AC-0676 is under clinical development by Accutar Biotechnology and currently in Phase I for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase I drugs for Marginal Zone B-cell Lymphoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AC-0676’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AC-0676 overview
AC-0676 is under development for the treatment of relapsed/refractory B-cell malignancies (hematological cancers), relapsed/refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), non-GCB diffuse large b-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), or Waldenström macroglobulinemia (WM). The drug candidate targets wild type and c481s mutated froms of tyrosine protein kinase BTK. It is administered through oral route and is being developed based on AI-empowered drug discovery platform.
It was also under development for the treatment of autoimmune disorders.
Accutar Biotechnology overview
Accutar Biotechnology (Accutar Biotech) is a pharmaceutical drug development company. The company’s pipeline products include AC0699 and AC0682 treats breast cancer; AC0176 for prostate cancer; AC0676 targets hematology oncology indications; multiple novel E3 ligases; and small molecule (precision oncology) for lung cancer and solid tumors. It uses an artificial intelligence (AI) platform, data evaluation, deep neural network-based docking platform (orbital), virtual screening, automatic and intelligent lead optimization platform and deep learning platform for preclinical drug discovery. Accutar Biotech is headquartered in Cranbury, New Jersey, the US.
For a complete picture of AC-0676’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
